VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Gilead Sciences, Inc. vs Moody's Corporation
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisMoody's Corporation
MCO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Moody's Corporation's moat claims, evidence, and risks.
View MCO analysisComparison highlights
- Moat score gap: Moody's Corporation leads (79 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); Moody's Corporation has 2 segments (53.5% in Moody's Investors Service (Credit Ratings)).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; Moody's Corporation has 5 across 4.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Moody's Corporation
Moody's Investors Service (Credit Ratings)
Credit ratings and ratings-related research
Global
Issuers, investors, regulators
Credit rating agency / research provider
53.5%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
Moody's Corporation strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Moody's Corporation segments
Full profile >Moody's Investors Service (Credit Ratings)
Oligopoly
Moody's Analytics (Risk & Data/Software)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.